Genetics and Human Health: Hereditary Factors and Disease Risk
A single nucleotide variant in the BRCA1 gene can raise a woman's lifetime risk of breast cancer above 70 percent — a stark illustration of how hereditary factors shape health outcomes before a person takes their first breath. This page covers the mechanisms by which genetic inheritance influences disease risk, the conditions most strongly tied to hereditary factors, and how clinicians and individuals use genetic information to make meaningful health decisions. The scope spans both single-gene disorders and the more complex terrain of multifactorial conditions where genes and environment interact.
Definition and scope
Genetics, in the context of human health, refers to the role that heritable variations in DNA sequence play in determining susceptibility to disease, response to treatment, and patterns of biological aging. The determinants of health include genetics as one foundational layer — not a destiny, but a probability landscape that clinicians increasingly know how to read.
The human genome contains approximately 3.2 billion base pairs encoding around 20,000 protein-coding genes (National Human Genome Research Institute). Variations within those genes range from single-letter spelling changes (single nucleotide polymorphisms, or SNPs) to large structural rearrangements involving entire chromosomal segments. Not all variants cause disease — the majority are neutral or their effects are too small to detect individually. But a meaningful subset carry well-characterized risk.
The field divides naturally into two broad territories:
- Monogenic (single-gene) disorders — caused by a mutation in one specific gene, following predictable inheritance patterns. Examples include cystic fibrosis, sickle cell disease, Huntington's disease, and hereditary hemochromatosis.
- Multifactorial (polygenic) conditions — shaped by the combined effect of dozens or hundreds of genetic variants, each contributing modest risk, amplified or muted by environmental exposures. Type 2 diabetes, coronary artery disease, and most common cancers fall into this category.
The distinction matters clinically because monogenic conditions often confer high predictive certainty, while polygenic risk scores describe population-level probabilities, not individual guarantees.
How it works
Genetic variants influence health through several distinct mechanisms. The clearest cases involve loss-of-function mutations — where a critical protein simply stops working. In familial hypercholesterolemia, for example, mutations in the LDLR gene disable LDL receptors, causing LDL cholesterol to accumulate in the bloodstream at levels that accelerate cardiovascular health deterioration decades earlier than typical onset.
Dominant inheritance requires only one altered copy of a gene (from one parent) to cause disease. Recessive inheritance requires two altered copies — one from each parent — meaning carriers with a single copy are generally unaffected but can pass the variant to children. This distinction drives genetic counseling decisions for families with known hereditary conditions.
Epigenetics adds another layer: environmental factors including diet, stress, and tobacco exposure (tobacco and health carries its own epigenetic fingerprint) can modify how genes are expressed without changing the underlying DNA sequence. This means that even a strong genetic predisposition is not a fixed outcome.
Pharmacogenomics — the application of genetic information to drug therapy — is increasingly embedded in clinical practice. The FDA's Table of Pharmacogenomic Biomarkers lists over 300 drug-gene interactions where a patient's genotype affects drug metabolism, efficacy, or toxicity (FDA Pharmacogenomics).
Common scenarios
Hereditary factors appear most prominently in clinical practice across three domains.
Cancer risk. Pathogenic variants in BRCA1 and BRCA2 account for 5–10 percent of all breast cancers and are associated with markedly elevated ovarian cancer risk (National Cancer Institute, BRCA fact sheet). Lynch syndrome, caused by mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS2), elevates lifetime colorectal cancer risk to between 40 and 80 percent depending on the specific variant. These are not obscure edge cases — Lynch syndrome affects approximately 1 in 300 people in the United States. Understanding hereditary cancer risk connects directly to cancer prevention overview strategies including enhanced surveillance and prophylactic interventions.
Cardiovascular and metabolic conditions. Familial hypercholesterolemia affects roughly 1 in 250 people globally, yet remains underdiagnosed (European Heart Journal, 2020). Monogenic forms of diabetes overview — including MODY (maturity-onset diabetes of the young) — are frequently misclassified as Type 1 or Type 2 diabetes, leading to suboptimal treatment. Correct genetic diagnosis changes the therapeutic approach entirely.
Pediatric and rare disease. Chromosomal conditions such as trisomy 21 (Down syndrome) arise from errors in chromosome number rather than single-gene mutations. Newborn screening programs in the United States test for more than 50 conditions at birth, most of them genetic, under the Recommended Uniform Screening Panel maintained by HHS (RUSP, HHS).
Decision boundaries
Genetic information is genuinely useful in defined circumstances and genuinely limited in others. Knowing the boundary matters.
When genetic testing changes management: Confirmed pathogenic BRCA1/2 variants justify intensified screening schedules, risk-reducing surgeries, and cascade testing of first-degree relatives. Pharmacogenomic results for cytochrome P450 enzyme variants (CYP2D6, CYP2C19) directly inform antidepressant and antiplatelet drug selection. In these scenarios, the test result connects to an actionable decision tree.
When it adds uncertainty without direction: Direct-to-consumer genetic tests for polygenic risk scores — such as those offered by 23andMe or AncestryHealth — provide probabilistic population-level estimates that are not equivalent to clinical genetic testing. A moderate polygenic risk score for coronary artery disease does not override health risk factors like smoking, blood pressure, and diet, all of which carry greater individual predictive weight.
The equity dimension: Polygenic risk scores built primarily from European-ancestry populations perform poorly in non-European populations — a limitation documented extensively in the literature and directly relevant to health equity. A risk score calibrated on one ancestry group applied broadly can systematically mis-stratify patients from other backgrounds, producing clinical recommendations that are at best imprecise and at worst harmful.
Genetic information, at its most useful, functions as one calibrated input among many in a broader model of preventive health — giving clinicians earlier, more precise windows into conditions that might otherwise announce themselves only through a first event.